TickerGuard
Buy Day today: Poor (52) Mixed market breadth · today: Core PCE (August) ≈
MYGN

Myriad Genetics Inc

Healthcare · Diagnostics & Research

4.10$ +3.2% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Income Statement

Myriad Genetics Inc (MYGN) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 191 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement MYGN
Line item Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
178 197 197 201 179 188 183 195 202 217 217 215 186 195 164 93 145 155 173 189 167 161 165 179 156 178 181 184 192 197 202 212 213 211 196 213 206 210 200 191 807
40 44 44 43 43 44 44 46 50 52 49 51 50 50 50 37 44 47 50 54 48 46 48 50 50 54 59 58 58 62 65 64 64 60 62 61 62 63 63 64 251
138 152 153 158 136 144 139 149 153 165 168 165 137 146 114 57 101 108 123 136 120 115 117 130 106 124 122 126 134 135 138 147 150 151 134 152 144 147 138 127 555
19 19 18 19 18 17 19 18 21 22 22 21 21 19 20 17 18 18 23 20 19 21 21 20 21 23 23 21 24 21 25 27 29 32 28 26 28 26 27 25 106
112 120 122 122 115 115 115 122 130 135 141 150 136 136 133 107 124 133 146 135 180 142 111 127 131 147 152 218 136 33 71 72 69 148 67 67 68 56 62 58 244
132 135 145 141 52 137 125 139 151 159 162 170 158 154 248 125 141 151 170 157 199 158 143 147 151 176 174 239 194 166 166 184 170 190 163 481 167 153 168 166 654
5.7 17 7.7 17 84 6.3 14 9.7 1.2 6.1 5.9 -5.6 -21 -8.8 -134 -68 -40 -48 -47 -21 -80 -43 -26 -18 -45 -52 -52 -114 -60 -31 -28 -37 -20 -39 -29 -329 -23 -5.7 -31 -39 -99
0.7 2.6 1.5 1.2 0.9 0.7 0.5 1.0 2.2 3.4 3.2 3.2 2.9 2.5 2.3 3.1 2.9 2.9 3.0 2.0 1.1 0.5 0.9 0.6 0.8 0.9 0.5 0.5 1.0 0.9 0.5 0.8 0.8 0.7 0.8 1.5 3.8 4.4 4.1 4.1 16
4.0 12 8.0 19 83 5.6 13 10 0.8 3.6 3.3 -7.7 -22 -11 -131 -59 -44 -56 -50 -3.8 40 -44 -26 -18 -44 -52 -53 -116 -61 -32 -26 -37 -21 -39 -29 -331 -26 -8.9 -34 -43 -112
5.2 6.2 3.8 6.1 4.5 -25 4.3 3.7 1.6 1.0 -3.6 -3.4 -1.7 -3.1 -16 -3.0 -29 -12 -10 0.9 15 -36 -5.9 -3.8 -9.1 -9.8 2.1 -1.9 0.1 -1.1 0.1 -0.5 0.9 3.4 -29 -0.1 1.2 -1.0 – 0.6 –
-1.2 5.9 4.2 13 79 31 9.1 6.5 -0.7 2.6 6.9 -4.2 -21 -8.3 -115 -55 -15 -44 -40 -4.7 25 -7.6 -21 -14 -35 -42 -55 -116 -61 -31 -26 -37 -22 -43 -0.1 -331 -27 -7.9 -34 -43 -113
14 28 22 33 97 19 27 26 21 25 25 14 -1.2 9.3 -111 -38 -23 18 -28 15 55 -30 -13 -4.4 -30 -38 -33 -102 -46 -16 -9.7 -21 -4.8 -24 -14 -315 -9.8 8.1 -18 -26 -45

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?